

**Sydney Neuro Oncology  
Group Limited**

Financial report  
For the year ended 30 June 2016

TABLE OF CONTENTS

Directors' report ..... 1 - 4

Auditor's independence declaration ..... 5

Financial report

    Statement of profit or loss and other comprehensive income ..... 6

    Statement of financial position ..... 7

    Statement of changes in equity ..... 8

    Statement of cash flows ..... 9

    Notes to financial statements ..... 10 - 16

Directors' declaration ..... 17

Independent auditor's report ..... 18 - 20

## DIRECTORS' REPORT

The directors present their report together with the financial report of Sydney Neuro Oncology Group Limited for the year ended 30 June 2016 and auditor's report thereon. This financial report has been prepared in accordance with Australian Accounting Standards.

### Directors names

The names of the directors in office at any time during or since the end of the year are:

Dr Raymond John Cook [Appointed 25 October 2000]

Dr Michael Thomas Biggs [Appointed 25 October 2000]

A/Prof Helen Ruth Wheeler [Appointed 25 October 2000]

A/Prof Michael Back [Appointed 25 November 2009]

Dr Gordon Duncan Charles Dandie [Appointed 8 September 2004]

Mr Gregory Scott Brown [Appointed 17 August 2004]

Mr John Charles Ballard [Appointed 19 July 2006]

Mrs Suzane Peponis-Brisimis [Appointed 23 February 2016]

The directors have been in office since the start of the year to the date of this report unless otherwise stated.

### Results

The profit of the company for the year after providing for income tax amounted to \$375,595.

### Significant changes in state of affairs

There were no significant changes in the company's state of affairs that occurred during the financial year, other than those referred to elsewhere in this report.

### Company objectives

*The overall objectives of the company are:*

To enhance the management of brain tumours through targeted research, information sharing and constant scrutiny of treatment options;

To enhance the management of brain tumours by providing a coordinated group rather than a solitary doctor making all the critical decisions;

To coordinate the research into various radiation and drug protocols used in advanced treatment of malignant tumours;

To provide support to patients and carers;

To collect data on the natural history and management of brain tumours, specifically to scrutinise the effect of various treatment protocols on the outcome of these tumours.

## DIRECTORS' REPORT

### Company objectives (Continued)

*Principal strategies to achieve these objectives are:*

The group is involved in research projects that span epidemiology, diagnostic imaging, surgical approaches, tumour biology and drug trials;

The unit itself is not institution specific and although based in the Northern Sydney Area Health Services it is by no means specific to that area;

The organisation is a non-profit organisation, any profit through donations will be ploughed back into research.

### Principal activities

The principal activity of the company during the year was Neurosurgical Research.

No significant change in the nature of these activities occurred during the year.

### Company Performance

Working with a comprehensive database, the Group is able to assess the multiple variables that are involved in the overall management of tumours. This includes epidemiological data such as the effect of mobile phones on the incidence of brain tumours and the effect of relatively newer prescribed drugs such as Thalidomide/Temozolamide on the outcome of malignant tumours. This information is provided in peer review medical journals and made readily available to the public via patient support groups and internet profiles.

The Sydney Neuro-Oncology Group also recognises the need for ongoing support for the patients diagnosed with brain tumours and their family members. It has supported the development of a Brain Tumour Support Group; the first of its kind in NSW. The purpose of the support group is to provide education about brain tumours as well as an environment where patients and families can meet and share their experiences.

### After balance date events

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the company, the results of those operations, or the state of affairs of the company in future financial years.

### Likely developments

The company expects to maintain the present status and level of operations.

### Information on directors

<b>Dr Raymond John Cook</b>	Chairman
Qualifications	MBBS (Hons), FRACS
Experience	Director since 25 October 2000

## DIRECTORS' REPORT

### Information on directors (Continued)

<b>Dr Michael Thomas Biggs</b>	Director
Qualifications	MBBS, FRACS
Experience	Director since 25 October 2000
<b>A/Prof Helen Ruth Wheeler</b>	Director
Qualifications	MBBS, FRACS
Experience	Director since 25 October 2000
<b>A/Prof Michael Back</b>	Director
Qualifications	MBBS , FRANZCR, MBA
Experience	Director since 25 November 2009
<b>Dr Gordon Duncan Charles Dandie</b>	Director
Qualifications	MBBS, FRACS
Experience	Director since 8 September 2004
<b>Mr Gregory Scott Brown</b>	Director
Qualifications	None provided
Experience	Operations Executive Manager - Sydney Metropolitan Hospitals CEO of North Shore Private Hospital & Castlecrag Private Hospital Director of the Kolling Foundation, The Lincoln Centre, North Shore Heart Research Foundation and the Northern Cancer Institute Director since 17 August 2004
<b>Mr John Charles Ballard</b>	Director
Qualifications	Master of Business Administration from Columbia University, New York
Experience	MD & CEO of Southcorp Ltd MD Asia Pacific, United Biscuits Ltd MD Snack Foods, Amatil Ltd (now Coca-Cola Amatil Ltd) Chairman of Wattyl Ltd & Elders Ltd Director of Woolworths Ltd, Email Ltd, CSR Ltd and Rinker Ltd & Fonterra Co-Operative Ltd Trustee of the Sydney Opera House Trust  Currently : Director of Magellan Flagship Funds Ltd and International Ferro Metals Ltd Chairman of Advisory Boards Pacific Equity Partners Director since 19th July 2006

## DIRECTORS' REPORT

### Information on directors (Continued)

**Mrs Suzane Peponis-Brisimis** Director  
 Qualifications BA.MA.  
 Experience Company Director and Secretary, private property investment/development companies Director since 23rd February 2016  
 Special responsibilities

### Meetings of directors

Directors	Directors' meetings	
	Number eligible to attend	Number attended
Dr Raymond John Cook	7	7
Dr Michael Thomas Biggs	7	4
A/Prof Helen Ruth Wheeler	7	6
A/Prof Michael Back	7	5
Dr Gordon Duncan Charles Dandie	7	4
Mr Gregory Scott Brown	7	5
Mr John Charles Ballard	7	6
Mrs Suzane Peponis-Brisimis	3	3

### Members guarantee

The company is incorporated under the *Corporations Act 2001* and is a company limited by guarantee. If the company is wound up, the Constitution states that each member is required to contribute to a maximum of \$1 each towards meeting any outstandings and obligations of the company. At 30 June 2016 the number of members was 16. The combined total amount that members of the company are liable to contribute if the company is wound up is \$16.

### Auditor's independence declaration

A copy of the auditor's independence declaration under section 60-40 of the *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit for the financial year is provided with this report.

Signed on behalf of the board of directors.

Director: \_\_\_\_\_

  
Dr Raymond John Cook

Dated this 8 day of Nov 2016

**AUDITOR'S INDEPENDENCE DECLARATION  
TO THE DIRECTORS OF SYDNEY NEURO ONCOLOGY GROUP LIMITED**

In relation to the independent audit for the year ended 30 June 2016, to the best of my knowledge and belief there have been:

- (i) No contraventions of the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012*; and
- (ii) No contraventions of any applicable code of professional conduct.

CARL MILLINGTON

Partner

PITCHER PARTNERS

Sydney

Date:

**STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 30 JUNE 2016**

	Note	2016 \$	2015 \$
Revenue	2	801,108	485,271
Less: expenses			
Employee benefits expense		(358,052)	(402,083)
Materials and consumables used		(13,882)	(12,495)
Depreciation and amortisation expense	3	(6,296)	(3,052)
Research Expenses		(1,654)	(3,860)
Donations		(20,000)	(5,000)
Other expenses		<u>(25,629)</u>	<u>(31,527)</u>
		<u>(425,513)</u>	<u>(458,017)</u>
Profit before income tax expense		375,595	27,254
Other comprehensive income for the year		<u>-</u>	<u>-</u>
Total comprehensive income		<u><u>375,595</u></u>	<u><u>27,254</u></u>

The accompanying notes form part of these financial statements.



**STATEMENT OF FINANCIAL POSITION  
AS AT 30 JUNE 2016**

	Note	2016 \$	2015 \$
<b>Current assets</b>			
Cash and cash equivalents	4	668,469	298,343
Receivables	5	2,321	15,884
Other financial assets	6	<u>328,109</u>	<u>311,500</u>
<b>Total current assets</b>		<u>998,899</u>	<u>625,727</u>
<b>Non-current assets</b>			
Property, plant and equipment	7	<u>22,011</u>	<u>28,307</u>
<b>Total non-current assets</b>		<u>22,011</u>	<u>28,307</u>
<b>Total assets</b>		<u>1,020,910</u>	<u>654,034</u>
<b>Current liabilities</b>			
Payables	8	35,946	65,015
Provisions	9	<u>69,654</u>	<u>49,305</u>
<b>Total current liabilities</b>		<u>105,600</u>	<u>114,320</u>
<b>Total liabilities</b>		<u>105,600</u>	<u>114,320</u>
<b>Net assets</b>		<u>915,310</u>	<u>539,714</u>
<b>Equity</b>			
Retained earnings		<u>915,310</u>	<u>539,714</u>
<b>Total equity</b>		<u>915,310</u>	<u>539,714</u>

The accompanying notes form part of these financial statements.

**STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED 30 JUNE 2016**

	2016	2015
	\$	\$
<b>Total equity</b>		
Balance at beginning of the year	539,714	512,460
Movements in equity from:		
Retained earnings	<u>375,595</u>	<u>27,254</u>
Balance at the end of the year	<u>915,309</u>	<u>539,714</u>
<b>Retained earnings</b>		
Balance at beginning of the year	539,714	512,460
Profit for the year	<u>375,595</u>	<u>27,254</u>
Total comprehensive income	<u>375,595</u>	<u>27,254</u>
Balance at the end of the year	<u>915,309</u>	<u>539,714</u>

The accompanying notes form part of these financial statements.

**STATEMENT OF CASH FLOWS  
FOR THE YEAR ENDED 30 JUNE 2016**

	Note	2016 \$	2015 \$
<b>Cash flow from operating activities</b>			
Cost recoveries and other operating receipts		122,012	119,449
Operating grants and subsidies		110,000	110,000
Donations and fundraising revenue received		569,882	252,392
Payments to suppliers and employees		(429,514)	(391,231)
Dividends received		9,192	6,949
Interest received		<u>11,240</u>	<u>12,957</u>
<b>Net cash provided by operating activities</b>		<u><b>392,812</b></u>	<u><b>110,516</b></u>
<b>Cash flow from investing activities</b>			
Payment for property, plant and equipment		-	(30,727)
Proceeds / (Payments) for investments		<u>(22,686)</u>	<u>(12,224)</u>
<b>Net cash provided by / (used in) investing activities</b>		<u><b>(22,686)</b></u>	<u><b>(42,951)</b></u>
<b>Reconciliation of cash</b>			
Cash at beginning of the financial year		298,343	230,778
Net increase in cash held		<u>370,126</u>	<u>67,565</u>
<b>Cash at end of financial year</b>		<u><b>668,469</b></u>	<u><b>298,343</b></u>

The accompanying notes form part of these financial statements.

**NOTES TO FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2016**

**NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES**

The financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards - Reduced Disclosure Requirements, Interpretations and other applicable authoritative pronouncements of the Australian Accounting Standards Board and the *Corporations Act 2001*.

The financial report was approved by the directors as at the date of the directors' report.

The financial report is for the entity Sydney Neuro Oncology Group Limited as an individual entity. Sydney Neuro Oncology Group Limited is a company limited by guarantee, incorporated and domiciled in Australia. Sydney Neuro Oncology Group Limited is a not-for-profit entity for the purpose of preparing the financial statements.

The following is a summary of the material accounting policies adopted by the company in the preparation and presentation of the financial report. The accounting policies have been consistently applied, unless otherwise stated.

**(a) Basis of preparation of the financial report**

*Historical Cost Convention*

The financial report has been prepared under the historical cost convention, as modified by revaluations to fair value for certain classes of assets and liabilities as described in the accounting policies.

**(b) Revenue**

Dividend revenue is recognised when the right to receive a dividend has been established. Dividends received from associates and joint venture entities are accounted for in accordance with the equity method of accounting.

Interest revenue is recognised when it becomes receivable on a proportional basis taking in to account the interest rates applicable to the financial assets.

All revenue is measured net of the amount of goods and services tax (GST).

Revenue from donations/fundraising is recognised when received.

**(c) Contributions - Government Grants and Donations**

A non-reciprocal contribution or grant is recognised when the entity obtains control of the contribution or grant and it is probable that the economic benefits will flow to the entity, and the amount of the contribution or grant can be measured reliably.

If conditions attached to the contribution or grant that must be satisfied before the entity is eligible to receive the contribution, recognition of contribution or income is deferred until those conditions are met.

NOTES TO FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2016

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

**(d) Income tax**

No provision for income tax has been raised as the company is exempt from income tax under Division 50 of the *Income Tax Assessment Act 1997*.

**(e) Financial instruments**

*Fair value through profit or loss*

Investments in listed securities are carried at fair value through profit or loss. They are measured at their fair value at each reporting date and any increment or decrement in fair value from the prior period is recognised in profit or loss of the current period. Fair value of listed investments are based on closing bid prices at the reporting date.

**(f) Property, plant and equipment**

Each class of plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation and any accumulated impairment losses.

*Plant and equipment*

Plant and equipment is measured on the cost basis.

*Depreciation*

The depreciable amount of all property, plant and equipment is depreciated over their estimated useful lives commencing from the time the asset is held ready for use. Land and the land component of any class of property, plant and equipment is not depreciated.

**(g) Provisions**

Provisions are recognised when the company has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.

**NOTES TO FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2016**

**NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**(h) Employee benefits**

*(i) Short-term employee benefit obligations*

Liabilities arising in respect of wages and salaries, annual leave and any other employee benefits (other than termination benefits) expected to be settled wholly before twelve months after the end of the annual reporting period are measured at the (undiscounted) amounts based on remuneration rates which are expected to be paid when the liability is settled. The expected cost of short-term employee benefits in the form of compensated absences such as annual leave is recognised in the provision for employee benefits. All other short-term employee benefit obligations are presented as payables in the statement of financial position.

*(ii) Long-term employee benefit obligations*

The provision for other long-term employee benefits, including obligations for long service leave and annual leave, which are not expected to be settled wholly before twelve months after the end of the reporting period, are measured at the present value of the estimated future cash outflow to be made in respect of the services provided by employees up to the reporting date. Expected future payments incorporate anticipated future wage and salary levels, durations of service and employee turnover, and are discounted at rates determined by reference to market yields at the end of the reporting period on high quality corporate bonds that have maturity dates that approximate the terms of the obligations. Any remeasurements for changes in assumptions of obligations for other long-term employee benefits are recognised in profit or loss in the periods in which the change occurs.

Other long-term employee benefit obligations are presented as current liabilities in the statement of financial position if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting date, regardless of when the actual settlement is expected to occur. All other long-term employee benefit obligations are presented as non-current liabilities in the statement of financial position.

**(i) Goods and services tax (GST)**

Revenues, expenses and purchased assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Tax Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the statement of cash flows on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

**(j) Comparatives**

Where necessary, comparative information has been reclassified and repositioned for consistency with current year disclosures.

**NOTES TO FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2016**

	2016	2015
	\$	\$
<b>NOTE 2: REVENUE AND OTHER INCOME</b>		
Dividend income	9,192	6,949
Interest income	11,240	12,957
Donations and grants	<u>721,754</u>	<u>414,235</u>
	<u>742,186</u>	<u>434,141</u>
Other Income		
Gain / (loss) on fair value adjustments	(6,078)	(13,870)
Administration costs recovered	<u>65,000</u>	<u>65,000</u>
	<u>58,922</u>	<u>51,130</u>
	<u>801,108</u>	<u>485,271</u>
<b>NOTE 3: OPERATING PROFIT</b>		
Profit / (losses) before income tax has been determined after:		
Cost of sales		
- Purchases/Materials used	13,882	12,495
Depreciation		
- computer equipment	6,296	3,052
Research and development costs	1,654	3,860
Employee benefits	358,052	402,083
Loss on sale of investments	-	6,405
<b>NOTE 4: CASH AND CASH EQUIVALENTS</b>		
Cash at bank	<u>668,469</u>	<u>298,343</u>
<b>NOTE 5: RECEIVABLES</b>		
<b>CURRENT</b>		
Trade debtors	-	9,305
Other receivables	<u>2,321</u>	<u>6,579</u>
	<u>2,321</u>	<u>15,884</u>

**NOTES TO FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2016**

	2016	2015
	\$	\$
<b>NOTE 6: OTHER FINANCIAL ASSETS</b>		
<b>CURRENT</b>		
<i>Financial assets at fair value through profit or loss</i>		
Shares in listed corporations	<u>328,109</u>	<u>311,500</u>
All financial assets at fair value through profit or loss are held for trading.		
 <b>NOTE 7: PROPERTY, PLANT AND EQUIPMENT</b>		
<b>Plant and equipment</b>		
Computer equipment at cost	2,733	2,733
Accumulated depreciation	<u>(2,531)</u>	<u>(2,380)</u>
	202	353
Laboratory Equipment	30,727	30,727
Accumulated depreciation	<u>(8,918)</u>	<u>(2,773)</u>
	<u>21,809</u>	<u>27,954</u>
Total property, plant and equipment	<u>22,011</u>	<u>28,307</u>
 <b>(a) Reconciliations</b>		
Reconciliation of the carrying amounts of property, plant and equipment at the beginning and end of the current financial year		
 <i>Computer equipment</i>		
Opening carrying amount	353	633
Depreciation expense	<u>(151)</u>	<u>(280)</u>
Closing carrying amount	<u>202</u>	<u>353</u>
 <i>Laboratory Equipment</i>		
Opening carrying amount	27,955	-
Additions	-	30,728
Depreciation expense	<u>(6,146)</u>	<u>(2,773)</u>
Closing carrying amount	<u>21,809</u>	<u>27,955</u>



**NOTES TO FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2016**

	2016	2015
	\$	\$
<b>NOTE 8: PAYABLES</b>		
CURRENT		
<i>Unsecured liabilities</i>		
Sundry creditors and accruals	<u>35,946</u>	<u>65,015</u>

**NOTE 9: PROVISIONS**

CURRENT		
Employee benefits	(a) <u>69,654</u>	<u>49,305</u>
(a) Aggregate employee benefits liability	69,654	49,305

**NOTE 10: ECONOMIC DEPENDENCE**

The entity is reliant on the ongoing support of the North Shore Private Hospital. At the date of this report the Board of Directors has no reason to believe that the North Shore Private Hospital will not continue to support Sydney Neuro Oncology Group Limited.

**NOTE 11: EVENTS SUBSEQUENT TO REPORTING DATE**

There has been no matter or circumstance, which has arisen since 30 June 2016 that has significantly affected or may significantly affect:

- (a) the operations, in financial years subsequent to 30 June 2016, of the company, or
- (b) the results of those operations, or
- (c) the state of affairs, in financial years subsequent to 30 June 2016, of the company.

**NOTE 12: MEMBERS' GUARANTEE**

The company is incorporated under the *Corporations Act 2001* and is a company limited by guarantee. If the company is wound up, the Constitution states that each member is required to contribute to a maximum of \$1 each towards meeting any outstandings and obligations of the company. At 30 June 2016 the number of members was 16. The combined total amount that members of the company are liable to contribute if the company is wound up is \$16.

**NOTES TO FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2016**

	2016	2015
	\$	\$
<b>NOTE 13: ADDITIONAL INFORMATION PROVIDED - CHARITABLE FUNDRAISING ACT 1991</b>		
A. Total cost of fundraising	13,882	12,495
B. Gross proceeds of fundraising	611,754	304,235
C. Net Surplus from fundraising	597,872	291,740
D. Total cost of services	-	-
E. Total expenditure	425,513	458,017
F. Total income	801,108	485,271
 <b>(a) RATIOS</b>		
A/B	2.27%	4.10%
B/C	102.32%	104.28%
D/E	0%	0%
D/F	<u>0%</u>	<u>0%</u>

**(b) Note**

As noted the entity incurred direct costs in relation to the fundraising income received. Fundraising income received was by way of general donations, the sale of fundraising products (Beanies for Brains, Entertainment Books) and events. A portion of the entity's administration, general, meeting and employment costs are recouped from the North Shore Private Hospital by way of an administration charge.

## DIRECTORS' DECLARATION

The directors of the company declare that:

1. The financial statements and notes, as set out on pages 6 - 16, are in accordance with the *Australian Charities and Not-for-profits Commission Act 2012*: and
  - (a) comply with Australian Accounting Standards - Reduced Disclosure Requirements and the *Australian Charities and Not-for-profits Commission Act 2012*; and
  - (b) give a true and fair view of the financial position as at 30 June 2016 and performance for the year ended on that date of the company.
2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.
4. The provisions of the *Charitable Fundraising Act 1991 (NSW)* and *Charitable Fundraising Regulation 2008 (NSW)* have been complied with.
5. The internal controls exercised by the company are appropriate and effective in accounting for all income received and applied from fundraising appeals.

This declaration is made in accordance with a resolution of the Board of Directors.

Director: \_\_\_\_\_



Dr Raymond John Cook

Dated this  day of November 2016

**INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS OF SYDNEY NEURO ONCOLOGY GROUP LIMITED**

We have audited the accompanying financial report of Sydney Neuro Oncology Group Limited, which comprises the statement of financial position as at 30 June 2016, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

*Directors' Responsibility for the Financial Report*

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

*Auditor's Responsibility*

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance about whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS OF SYDNEY NEURO ONCOLOGY GROUP LIMITED**

*Independence*

In conducting our audit, we have complied with the independence requirements of the *Corporations Act 2001*.

*Basis for Qualified Opinion*

Cash donations are a significant source of fundraising revenue for the Sydney Neuro Oncology Group Limited. Sydney Neuro Oncology Group Limited has determined that it is impracticable to maintain effective internal controls over the collection of cash donations prior to entry into its financial records. Accordingly, as the evidence available to us regarding fundraising revenue from this source was limited, our audit procedures with respect to cash donations had to be restricted to the amounts recorded in the financial records. We therefore are unable to express an opinion whether cash donations recorded for the Sydney Neuro Oncology Group Limited are complete.

*Qualified Opinion*

Based on our audit, in our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion paragraph, we have not become aware of any matter that makes us believe that the financial report of Sydney Neuro Oncology Group Limited is not in accordance with the Australian Charities and Not-for-profits Commission Act 2012 including:

- (a) Giving a true and fair view of the Company's financial position as at 30 June 2016 and of its performance for the year ended on that date; and
- (b) Complying with Australian Accounting Standards - Reduced Disclosure Requirements and the Australian Charities and Not-for-profits Commission Act 2012

Qualified audit opinion pursuant to the Charitable Fundraising Act 1991

Based on our audit, in our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion paragraph, we have not become aware of any matter that makes us believe that the financial report of Sydney Neuro Oncology Group Limited is not in accordance with the Charitable Fundraising Act 1991 including:

- (a) The financial report gives a true and fair view of the financial result of fundraising appeal activities for the year ended 30 June 2016
- (b) The financial report has been properly drawn up, and the associated records properly kept, for the year ended 30 June 2016 in accordance with the Charitable Fundraising Act 1991 and the regulations

**INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS OF SYDNEY NEURO ONCOLOGY GROUP LIMITED**

- (c) Money received as a result of fundraising appeal activities conducted during the year ended 30 June 2016 as been properly accounted for and applied in accordance with the Charitable Fundraising Act 1991 and the regulations; and
- (d) There are reasonable grounds to believe the organisation will be able to pay its debts as and when they fall due.

CARL MILLINGTON

Partner

Date

PITCHER PARTNERS

Sydney